MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/105/0.1/20.12.24 Stock

Warrant

DE000ME1GAC0

Market Closed - Börse Stuttgart 12:51:12 2024-07-05 EDT
3.77 EUR +3.57% Intraday chart for MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/105/0.1/20.12.24
Current month-5.28%
3 months+38.10%
Date Price Change
24-07-05 3.77 +3.57%
24-07-04 3.64 +4.90%
24-07-03 3.47 -10.10%
24-07-02 3.86 -6.54%
24-07-01 4.13 +3.77%

Delayed Quote Börse Stuttgart

Last update July 05, 2024 at 12:51 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying NOVO NORDISK A/S
Issuer Morgan Stanley
WKN ME1GAC
ISINDE000ME1GAC0
Date issued 2023-10-03
Strike 105 $
Maturity 2024-12-20 (168 Days)
Parity 10 : 1
Emission price 0.95
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 4.23
Lowest since issue 0.73
Delta0.9x
Omega 3.086
Premium2.78x
Gearing3.43x
Moneyness 1.358
Difference Strike -37.37 $
Difference Strike %-35.59%
Spread 0.01
Spread %0.26%
Theoretical value 3.835
Implied Volatility 41.35 %
Total Loss Probability 15.31 %
Intrinsic value 3.470
Present value 0.3655
Break even 146.57 €
Theta-0.02x
Vega0.02x
Rho0.04x

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
More about the company

Ratings for Novo Nordisk A/S

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Consensus: Novo Nordisk A/S

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
974 DKK
Average target price
952.2 DKK
Spread / Average Target
-2.24%
Consensus